This is a preview of subscription content, log in via an institution to check access.
Notes
The study was supported by funding from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Reference
Thurgar E, et al. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer. Journal of Medical Economics : 18 Apr 2021. Available from: URL: https://doi.org/10.1080/13696998.2021.1917140
Rights and permissions
About this article
Cite this article
Pembrolizumab in dMMR/MSI-H unresectable or metastatic endometrial cancer: substantial gain in life-years at acceptable cost in the US. PharmacoEcon Outcomes News 877, 16 (2021). https://doi.org/10.1007/s40274-021-7665-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7665-4